Back to Search Start Over

Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.

Authors :
De Re V
Caggiari L
Repetto O
Mussolin L
Mascarin M
Source :
Journal of clinical medicine [J Clin Med] 2019 Oct 02; Vol. 8 (10). Date of Electronic Publication: 2019 Oct 02.
Publication Year :
2019

Abstract

: The ligation of programmed cell death 1 (PD-1) with programmed cell death ligand PD-L activates the immune checkpoint leading to T-cell dysfunction, exhaustion, and tolerance, especially in Hodgkin lymphoma (HL) where the PD-L/ Janus kinase (Jak) signaling was frequently found altered. Anti-PD-1 or anti-PD-L1 monoclonal antibodies can reverse this immune checkpoint, releasing the brake on T-cell responses. The characterization of the mechanisms regulating both the expression of PD-1 and PD-L and their function(s) in HL is ongoing. We provide in this review the recent findings focused on this aim with special attention on the major research topics, such as adverse events and resistance to PD-1-PD-L1 inhibitor treatment, together with a part about angiogenesis, extracellular vesicles, and microbiome in HL pathogenesis.<br />Competing Interests: The authors declare no conflicts of interest.

Details

Language :
English
ISSN :
2077-0383
Volume :
8
Issue :
10
Database :
MEDLINE
Journal :
Journal of clinical medicine
Publication Type :
Academic Journal
Accession number :
31581738
Full Text :
https://doi.org/10.3390/jcm8101596